Condition 101 About Myasthenia Gravis Congenital

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Top Global Doctors For Myasthenia Gravis Congenital

Latest Advances On Myasthenia Gravis Congenital

  • Condition: Late-Onset Congenital Myasthenic Syndrome due to Heterozygous DOK7 Mutation
  • Journal: Neuromuscular disorders : NMD
  • Treatment Used: Steroids, Intravenous Human Immunoglobulin, and Acetylcholinesterase Inhibitors, and Targeted Therapies
  • Number of Patients: 1
  • Published —
This case report discusses a 67-year-old female patient diagnosed with late-onset congenital myasthenic syndrome due to a heterozygous DOK7 mutation treated with steroids, intravenous human immunoglobulin, and acetylcholinesterase inhibitors with no response.

Clinical Trials For Myasthenia Gravis Congenital

Clinical Trial
  • Status: Active, not recruiting
  • Phase: N/A
  • Intervention Type: Drug
  • Participants: 22
  • Start Date: June 2001
Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)